PharmaCyte Biotech, Inc.

NASDAQ: PMCB · Healthcare · Biotechnology

PublicHQ Las Vegas, NV · ClarkCIK 0001157075Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

61C

FH 69DQ 56GM —SS 35

v0.1 · 55/100 weight · provisional

↑ return on equity, return on assets · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

$30.7M

Employees

Market cap

$4.9M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income$30.7M$30.7M2025

Operating income-$4.4M-$4.4M2025

Total assets$55.2M$55.2M2025

Liabilities$3.3M$3.3M2025

Equity$51.9M$51.9M2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

FY20

FY21

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

PharmaCyte Biotech, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a Infinity% net margin.

Peers · Healthcare

Healthy Extracts Inc.67B Tempest Therapeutics, Inc.26D Mosaic ImmunoEngineering Inc.——Processa Pharmaceuticals, Inc.38D

Neighbors

Clark →

Las Vegas Sands Corp.$13.0B80B+MGM Resorts International$17.5B68B Wynn Resorts, Limited$7.1B65B MP Materials Corp.$224.4M49D Bitmine Immersion Technologies, Inc.$6.1M47D Boyd Gaming Corporation$4.1B77B+

Key facts

CEOJoshua N. Silverman

SectorHealthcare

IndustryBiotechnology

HeadquartersLas Vegas, NV

ExchangeNASDAQ: PMCB

Employees2

IPO date2013-01-02

Latest filings

8-K2026-04-02 10-Q2026-03-17 DEF 14A2026-03-09 10-Q2025-12-18 8-K2025-12-05 8-K2025-10-31 DEF 14A2025-10-06 10-Q2025-09-15

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.